Korro Bio (KRRO) Return on Capital Employed (2019 - 2026)
Korro Bio's (KRRO) quarterly Return on Capital Employed came in at 87.66% in Q1 2026, down 4024.0% YoY from 2.23% in Q1 2025, and up 9.65% on a QoQ basis from 97.03% in Q4 2025.
Korro Bio (KRRO) Return on Capital Employed (2019 - 2026) Analysis & Trends
Korro Bio (KRRO) has 8 years of Return on Capital Employed data on file, last reported at 87.66% in Q1 2026.
- Quarterly Return on Capital Employed fell 4024.0% year-over-year to 87.66% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 87.66% (down 4024.0% YoY) and the FY2025 annual result came in at 77.15%, down 3318.0% from the prior year.
- Return on Capital Employed grew to 87.66% in Q1 2026, from 97.03% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 41.11% in Q3 2024 to a low of 97.33% in Q3 2023.
- A 5-year average of 64.06% and a median of 61.34% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2024 — Return on Capital Employed jumped 5623 bps — and 2025, when it sank 5523 bps.
- Tracing KRRO's Return on Capital Employed over 5 years: stood at 61.34% in 2022, then retreated by 20 bps to 73.81% in 2023, then jumped by 43 bps to 41.79% in 2024, then slumped by 132 bps to 97.03% in 2025, then advanced by 10 bps to 87.66% in 2026.
- The last three Return on Capital Employed figures came in at 87.66% (Q1 2026), 97.03% (Q4 2025), and 60.44% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | Korro Bio | 228.60 Mn | 113.56 Mn | - | -68.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -68.47% |
| Mar 31, 2026 | -87.66% |
| Dec 31, 2025 | -97.03% |
| Sep 30, 2025 | -60.44% |
| Jun 30, 2025 | -56.59% |
| Mar 31, 2025 | -47.42% |
| Dec 31, 2024 | -41.79% |
| Sep 30, 2024 | -41.11% |
| Jun 30, 2024 | -43.33% |
| Mar 31, 2024 | -43.22% |
| Dec 31, 2023 | -73.81% |
| Sep 30, 2023 | -97.33% |
| Jun 30, 2023 | -64.50% |
| Mar 31, 2023 | -85.12% |
| Dec 31, 2022 | -61.34% |
| Sep 30, 2022 | -70.15% |
| Jun 30, 2022 | -64.67% |
| Mar 31, 2022 | -53.44% |
| Dec 31, 2021 | -46.08% |
| Sep 30, 2021 | -36.34% |